Last reviewed · How we verify
Lamivudine plus adefovir
At a glance
| Generic name | Lamivudine plus adefovir |
|---|---|
| Also known as | Zeffix, Hepsera, lamivudine (zeffix), adefovir (hepsera) |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Effects of Antiviral Therapy on Patients With HBV-related HCC
- Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B (PHASE4)
- A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV (PHASE2)
- The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs (PHASE2)
- Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 (PHASE2)
- Extension Study of Carvedilol RCT Study (NA)
- Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamivudine plus adefovir CI brief — competitive landscape report
- Lamivudine plus adefovir updates RSS · CI watch RSS
- Taipei Veterans General Hospital, Taiwan portfolio CI